The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Fondaparinux Compared with Enoxaparin for the Prevention of Venous Thromboembolism after Hip-Fracture Surgery
Abstract
BACKGROUND: Surgery for hip fracture carries a high risk of venous thromboembolism, despite the use of current thromboprophylactic treatments. Fondaparinux, a synthetic pentasaccharide, is a new antithrombotic agent that may reduce this risk. METHODS: In a double-blind study, were randomly assigned 1711 consecutive patients undergoing surgery for fracture of the upper third of the femur to receive subcutaneous doses of either 2.5 mg of fondaparinux once daily, initiated postoperatively, or 40 mg of enoxaparin once daily, initiated preoperatively, for at least five days. The primary efficacy outcome was venous thromboembolism up to postoperative day 11. Venous thromboembolism was defined as deep-vein thrombosis detected by mandatory bilateral venography, documented symptomatic deep-vein thrombosis, or documented symptomatic pulmonary embolism. The main safety outcomes were major bleeding and mortality from all causes. The duration of follow-up was six weeks. RESULTS: The incidence of venous thromboembolism by day 11 was 8.3 percent (52 of 626 patients) in the fondaparinux group and 19.1 percent (119 of 624 patients) in the enoxaparin group (P<0.001). The reduction in risk with fondaparinux was 56.4 percent (95 percent confidence interval, 39.0 to 70.3 percent). There were no significant differences between the two groups in the incidence of death or clinically relevant bleeding. CONCLUSIONS: In patients undergoing surgery for hip fracture, fondaparinux was more effective than enoxaparin in preventing venous thromboembolism and equally safe.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Heit, J. A., Clagett, G. P., Pineo, G. F., Colwell, C. W., Anderson, F. A., & Wheeler, H. B. (2001) · Chest · doi:10.1378/chest.119.1_suppl.132s · Cited by 4,373
(2000) · The Lancet · doi:10.1016/s0140-6736(00)02110-3 · Cited by 1,076
Roentgen Diagnosis of Venous Thrombosis in the Leg
Rabinov, K. (1972) · Archives of Surgery · doi:10.1001/archsurg.1972.04180020014004 · Cited by 740
The Unique Antithrombin III Binding Domain of Heparin: A Lead to New Synthetic Antithrombotics
van Boeckel, C. A. A., & Petitou, M. (1993) · Angewandte Chemie International Edition in English · doi:10.1002/anie.199316713 · Cited by 382
A Synthetic Pentasaccharide for the Prevention of Deep-Vein Thrombosis after Total Hip Replacement
Turpie, A. G. G., Gallus, A. S., & Hoek, J. A. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103013440901 · Cited by 380
Self-citation(1990) · JAMA · doi:10.1001/jama.263.20.2753 · Cited by 376
Eriksson, B. I., Wille-Jørgensen, P., Kälebo, P., Mouret, P., Rosencher, N., Bösch, P., Baur, M., Ekman, S., Bach, D., Lindbratt, S., et al. (1997) · New England Journal of Medicine · doi:10.1056/nejm199711063371901 · Cited by 370
Self-citation
Cited by
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Self-citationPrevention of Venous Thromboembolism
Geerts, W. H., Bergqvist, D., Pineo, G. F., Heit, J. A., Samama, C. M., Lassen, M. R., & Colwell, C. W. (2008) · Chest · doi:10.1378/chest.08-0656 · Cited by 3,829
Self-citationKahn (2012) · doi:10.1378/chest.11-2296 · Cited by 2,693
Prevention of VTE in Orthopedic Surgery Patients
Falck-Ytter, Y., Francis, C. W., Johanson, N. A., Curley, C., Dahl, O. E., Schulman, S., Ortel, T. L., Pauker, S. G., & Colwell, C. W. (2012) · Chest · doi:10.1378/chest.11-2404 · Cited by 1,930
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Self-citationHeparin and Low-Molecular-Weight Heparin
Hirsh, J., & Raschke, R. (2004) · Chest · doi:10.1378/chest.126.3_suppl.188s · Cited by 971
Hirsh, J., Bauer, K. A., Donati, M. B., Gould, M., Samama, M. M., & Weitz, J. I. (2008) · Chest · doi:10.1378/chest.08-0689 · Cited by 755
Self-citationTurpie, A. G. G. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.16.1833 · Cited by 736
Self-citationBauer, K. A., Eriksson, B. I., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011099 · Cited by 666
Self-citationKUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Turpie, A. G., Bauer, K. A., Eriksson, B. I., & Lassen, M. R. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08648-8 · Cited by 537
Self-citationThe Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Hirsh, J., Guyatt, G., Albers, G. W., & Schünemann, H. J. (2004) · Chest · doi:10.1378/chest.126.3_suppl.172s · Cited by 411
Relationship Between Deep Venous Thrombosis and the Postthrombotic Syndrome
Kahn, S. R., & Ginsberg, J. S. (2004) · Archives of Internal Medicine · doi:10.1001/archinte.164.1.17 · Cited by 405
Goldhaber, S. Z. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16004-2 · Cited by 348
Eriksson, B. I. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.11.1337 · Cited by 345
Self-citationAgnelli, G., Bergqvist, D., Cohen, A. T., Gallus, A. S., & Gent, M. (2005) · British Journal of Surgery · doi:10.1002/bjs.5154 · Cited by 337
Bijsterveld, N. R., Moons, A. H., Boekholdt, S. M., van Aken, B. E., Fennema, H., Peters, R. J. G., Meijers, J. C. M., Büller, H. R., & Levi, M. (2002) · Circulation · doi:10.1161/01.cir.0000038501.87442.02 · Cited by 316
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., & Misselwitz, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3185 · Cited by 297
Carbohydrate-based drugs launched during 2000−2021
Cao, X., Du, X., Jiao, H., An, Q., Chen, R., Fang, P., Wang, J., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.05.020 · Cited by 267
Guidelines on the use and monitoring of heparin
Baglin, T., Barrowcliffe, T. W., Cohen, A., Greaves, M., & the British Committee for Standards in Haematology (2006) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05953.x · Cited by 262
Methodological issues in trials assessing primary prophylaxis of venous thrombo-embolism
Thabut, G., Estellat, C., Boutron, I., Samama, C. M., & Ravaud, P. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi587 · Cited by 11
Metadata
- Authors
- Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2001-11
- Volume
- 345
- Issue
- 18
- Pages
- 1298-1304
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2000130043
- Cited by
- 631
- References
- 20
- FWCI
- 38.14
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.